Research report | 10/8/14
The Value of New Medicines
10/8/14 - The cost of a medicine can be calculated rather easily. But cost is not the same thing as value. For medicines to be used efficiently, knowing value is crucial.
The Value of New Medicines explains and critiques the concept of value, which has become a central focus of both scientific studies and health care policy. This book presents a framework for answering questions about value in an objective and verifiable way that is useful for policy making, and describes how to ensure that the introduction and use of medicines is based on value. Whilst the focus is on Sweden, the analysis and policy recommendations also may be relevant for other countries that are developing new policies, institutions and mechanisms to encourage the efficient and equitable introduction and use of new medicines under stringent economic conditions.
The report highlights the need to:
- Collect and analyse data from actual clinical practice to improve understanding of the effects, benefits and cost of medicines as a basis for assessing value
- Adopt sound decision-making processes that are consistent across the health care system
- Abolish price controls and permit prices of medicines to differ based on their benefits
- Create payment mechanisms that recognise that the value of a medicine can vary depending on the disease it is used to treat
- Analyse regional variations in patterns of use and treatment costs as the basis for policies that optimise the use of medicines
- Create incentives for best use and continuous evaluation of new medicines.
Bengt Jönsson, PhD, Emeritus Professor at the Stockholm School of Economics, is an internationally respected health economist and currently Vice Chair of the European Commission Expert Panel on Effective Ways of Investing in Health.
Katarina Steen Carlsson, PhD, is Research Director at the Swedish Institute for Health Economics (IHE) and a Researcher in health economics at Lund University.
The Value of New Medicines is a translation of the final report of a research programme entitled The Value of New Pharmaceuticals, a project of the Centre for Business and Policy Studies (SNS) in Sweden. The purpose of the research programme has been to contribute knowledge to support decision-making that affects access to new medicines and determines how medicines are used.
Download: the_value_of_new_medicines_web.pdf
ISBN 978-91-86949-60-0
184 pages
Released October 8 2014
Other research report on Health Care
Research report Health CareCoordinating care of the multimorbid elderly in Sweden – lessons learned from practice and research
Older patients face medical risks as coordination between municipalities and regions is failing. Clearer central government instructions regarding these types of collaborations are necessary, according to Paula Blomqvist and Ulrika Winblad in a new SNS report.
Research report Health CareCovid-19 in nursing homes as experienced by employees
Employees highlight great challenges in nursing homes during the pandemic. Their experiences offer important lessons for the future, according to Sara Erlandsson, Petra Ulmanen and Sara Wittzell in a new SNS report.
Research report Health CareReliable Control and Organization of Welfare
Trust-based governance has been introduced in several Swedish municipalities and regions. However, trust is not something that can be mandated from above, according to six researchers in the fields of work science and business administration in a new SNS report.- Research report Health Care
Measuring the Value of Elderly Care
Swedish elderly care has undergone significant changes in recent years and is now being developed using new welfare technologies. But is this in line with what the elderly want? Without properly analyzing what the elderly want, this development risks reducing their quality of life, according to researchers Sara Olofsson and Ulf Persson in a new SNS report.